The efficacy of SGLT-2 inhibitors in treating hepatic steatosis and fibrosis utilizing several imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease was investigated in this systematic review and meta-analysis of sixteen randomized controlled trials. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.